Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech, Sysmex end partnership:

This article was originally published in Clinica

Executive Summary

Diagnostics specialist Matritech has regained full rights to its NMP 179 cervical cancer technology, after terminating a worldwide license agreement with its development partner Sysmex. The companies will end their collaboration, initiated in 2002 (see Clinica No 1035, p 14), to develop an automated process of screening cervical cell specimens that would combine Matritech's patented biomarker with Sysmex' flow cytometry know-how. The move comes after Newton, Massachusetts-based Matritech agreed to be acquired by Inverness Medical Innovations in August (see Clinica No 1271, p 3). The use of NMP179 protein biomarker in Pap tests could help increase the accuracy of visually identifying cervical cells which need inspection by pathologists, according to the company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel